Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kura Oncology (KURA) EBIT Margin: 2024-2025

Historic EBIT Margin for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to -385.53%.

  • Kura Oncology's EBIT Margin fell 1492048.00% to -385.53% in Q3 2025 from the same period last year, while for Sep 2025 it was -482.11%, marking a year-over-year change of. This contributed to the annual value of -358.55% for FY2024, which is 1106248.00% down from last year.
  • As of Q3 2025, Kura Oncology's EBIT Margin stood at -385.53%, which was up 18.89% from -475.31% recorded in Q2 2025.
  • Kura Oncology's 5-year EBIT Margin high stood at 14,534.95% for Q3 2024, and its period low was -475.31% during Q2 2025.
  • In the last 2 years, Kura Oncology's EBIT Margin had a median value of 5,571.96% in 2024 and averaged 6,623.07%.
  • Data for Kura Oncology's EBIT Margin shows a maximum YoY slumped of 1,492,048bps (in 2025) over the last 5 years.
  • Over the past 2 years, Kura Oncology's EBIT Margin (Quarterly) stood at 5,571.96% in 2024, then tumbled by 1,492,048bps to -385.53% in 2025.
  • Its EBIT Margin was -385.53% in Q3 2025, compared to -475.31% in Q2 2025 and -458.61% in Q1 2025.